Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock

61.11  +5.8 (+10.49%)

After market: 61.11 0 (0%)

Fundamental Rating

7

Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 195 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes CORT very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year CORT was profitable.
CORT had a positive operating cash flow in the past year.
Each year in the past 5 years CORT has been profitable.
In the past 5 years CORT always reported a positive cash flow from operatings.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

CORT has a Return On Assets of 18.08%. This is amongst the best in the industry. CORT outperforms 97.85% of its industry peers.
The Return On Equity of CORT (22.20%) is better than 94.62% of its industry peers.
CORT's Return On Invested Capital of 18.79% is amongst the best of the industry. CORT outperforms 94.62% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly below the industry average of 43.99%.
Industry RankSector Rank
ROA 18.08%
ROE 22.2%
ROIC 18.79%
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

1.3 Margins

The Profit Margin of CORT (22.56%) is better than 94.62% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
With an excellent Operating Margin value of 22.81%, CORT belongs to the best of the industry, outperforming 89.25% of the companies in the same industry.
In the last couple of years the Operating Margin of CORT has declined.
CORT has a better Gross Margin (98.44%) than 98.39% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
Industry RankSector Rank
OM 22.81%
PM (TTM) 22.56%
GM 98.44%
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CORT has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 29.26 indicates that CORT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 29.26, CORT belongs to the best of the industry, outperforming 94.09% of the companies in the same industry.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 29.26
ROIC/WACC1.76
WACC10.7%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.3 Liquidity

CORT has a Current Ratio of 3.70. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.70, CORT perfoms like the industry average, outperforming 55.38% of the companies in the same industry.
CORT has a Quick Ratio of 3.64. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT's Quick ratio of 3.64 is in line compared to the rest of the industry. CORT outperforms 57.53% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.64
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.56% over the past year.
CORT shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.00% yearly.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 39.65%.
CORT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.94% yearly.
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%

3.2 Future

The Earnings Per Share is expected to grow by 49.09% on average over the next years. This is a very strong growth
Based on estimates for the next years, CORT will show a very strong growth in Revenue. The Revenue will grow by 28.39% on average per year.
EPS Next Y46.02%
EPS Next 2Y37.12%
EPS Next 3Y58.77%
EPS Next 5Y49.09%
Revenue Next Year45.26%
Revenue Next 2Y30.42%
Revenue Next 3Y32.89%
Revenue Next 5Y28.39%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 48.50, CORT can be considered very expensive at the moment.
CORT's Price/Earnings ratio is rather cheap when compared to the industry. CORT is cheaper than 80.65% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.29. CORT is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 34.21, which means the current valuation is very expensive for CORT.
CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 77.42% of the companies in the same industry.
CORT's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.44.
Industry RankSector Rank
PE 48.5
Fwd PE 34.21
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 76.88% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 79.57% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 44.93
EV/EBITDA 40.02
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of CORT may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 58.77% in the coming years.
PEG (NY)1.05
PEG (5Y)8.09
EPS Next 2Y37.12%
EPS Next 3Y58.77%

More info and screens

0

5. Dividend

5.1 Amount

CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (1/21/2025, 8:00:00 PM)

After market: 61.11 0 (0%)

61.11

+5.8 (+10.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-12 2025-02-12/amc
Inst Owners87.03%
Inst Owner Change0.04%
Ins Owners6.48%
Ins Owner Change1.32%
Market Cap6.40B
Analysts83.64
Price Target76.4 (25.02%)
Short Float %17.21%
Short Ratio17.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.47%
Min EPS beat(2)36.4%
Max EPS beat(2)42.54%
EPS beat(4)4
Avg EPS beat(4)24.19%
Min EPS beat(4)6.4%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.73%
EPS beat(12)9
Avg EPS beat(12)12.47%
EPS beat(16)12
Avg EPS beat(16)11.79%
Revenue beat(2)2
Avg Revenue beat(2)3.76%
Min Revenue beat(2)3.45%
Max Revenue beat(2)4.07%
Revenue beat(4)4
Avg Revenue beat(4)3.03%
Min Revenue beat(4)1.93%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)1.69%
Revenue beat(12)7
Avg Revenue beat(12)-0.35%
Revenue beat(16)8
Avg Revenue beat(16)-1.46%
PT rev (1m)0%
PT rev (3m)14.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.5%
EPS NY rev (1m)0%
EPS NY rev (3m)22.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)21.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.66%
Valuation
Industry RankSector Rank
PE 48.5
Fwd PE 34.21
P/S 10.19
P/FCF 44.93
P/OCF 44.28
P/B 10.02
P/tB 10.02
EV/EBITDA 40.02
EPS(TTM)1.26
EY2.06%
EPS(NY)1.79
Fwd EY2.92%
FCF(TTM)1.36
FCFY2.23%
OCF(TTM)1.38
OCFY2.26%
SpS6
BVpS6.1
TBVpS6.1
PEG (NY)1.05
PEG (5Y)8.09
Profitability
Industry RankSector Rank
ROA 18.08%
ROE 22.2%
ROCE 21.79%
ROIC 18.79%
ROICexc 44.52%
ROICexgc 44.52%
OM 22.81%
PM (TTM) 22.56%
GM 98.44%
FCFM 22.67%
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
ROICexc(3y)84.97%
ROICexc(5y)97.2%
ROICexgc(3y)84.97%
ROICexgc(5y)97.2%
ROCE(3y)25.29%
ROCE(5y)26.04%
ROICexcg growth 3Y-22.27%
ROICexcg growth 5Y-10.98%
ROICexc growth 3Y-22.27%
ROICexc growth 5Y-10.98%
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 197.92%
Cap/Sales 0.33%
Interest Coverage 250
Cash Conversion 100.13%
Profit Quality 100.49%
Current Ratio 3.7
Quick Ratio 3.64
Altman-Z 29.26
F-Score8
WACC10.7%
ROIC/WACC1.76
Cap/Depr(3y)36.26%
Cap/Depr(5y)101.19%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.19%
Profit Quality(3y)128.87%
Profit Quality(5y)134.44%
High Growth Momentum
Growth
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
EPS Next Y46.02%
EPS Next 2Y37.12%
EPS Next 3Y58.77%
EPS Next 5Y49.09%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%
Revenue Next Year45.26%
Revenue Next 2Y30.42%
Revenue Next 3Y32.89%
Revenue Next 5Y28.39%
EBIT growth 1Y45.99%
EBIT growth 3Y-5.76%
EBIT growth 5Y3.69%
EBIT Next Year53.38%
EBIT Next 3Y45.42%
EBIT Next 5Y26.86%
FCF growth 1Y4.95%
FCF growth 3Y-5.59%
FCF growth 5Y1.92%
OCF growth 1Y6.09%
OCF growth 3Y-5.8%
OCF growth 5Y1.89%